Venous thromboembolism and heparin use in COVID-19 patients: juggling between pragmatic choices, suggestions of medical societies and the lack of guidelines
Open Access
- 4 May 2020
- journal article
- editorial
- Published by Springer Science and Business Media LLC in Journal of Thrombosis and Thrombolysis
- Vol. 50 (1), 68-71
- https://doi.org/10.1007/s11239-020-02125-4
Abstract
No abstract availableThis publication has 33 references indexed in Scilit:
- Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 studyAnnals Of Oncology, 2019
- Acute thrombotic vascular events complicating influenza-associated pneumoniaRespiratory Medicine Case Reports, 2019
- American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patientsBlood Advances, 2018
- More than an anticoagulant: Do heparins have direct anti-inflammatory effects?Thrombosis and Haemostasis, 2017
- Heparin prevents Zika virus induced-cytopathic effects in human neural progenitor cellsAntiviral Research, 2017
- A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction ScoreJournal of Thrombosis and Haemostasis, 2010
- The anti-inflammatory effects of heparin and related compoundsThrombosis Research, 2008
- Coronaviridaeand SARS-associated Coronavirus Strain HSR1Emerging Infectious Diseases, 2004
- Herpesviruses and heparan sulfate: an intimate relationship in aid of viral entryJCI Insight, 2001
- Herpesviruses and heparan sulfate: an intimate relationship in aid of viral entryJCI Insight, 2001